First volunteers receive doses in Democratic Republic of Congo vaccine trial

The TUMAINI clinical study is testing if the Ervebo vaccine can reduce severe illness and death from the Bundibugyo virus using a ring-vaccination strategy.

First volunteers receive doses in Democratic Republic of Congo vaccine trial
Photo: Yeni Safak English

The first four volunteers have received doses in a clinical study in the Democratic Republic of Congo to determine if the existing Ervebo Ebola vaccine can reduce severe illness and death from the Bundibugyo virus. The study, named TUMAINI, began on Friday.

Researchers are examining whether Ervebo, which is known to be effective against the Zaire Ebola virus, can reduce severe disease and death from the Bundibugyo strain rather than prevent infection entirely. Investigators are using a ring-vaccination strategy that involves immunizing people who have been in close contact with confirmed Ebola patients or otherwise exposed to the virus.

Two vaccination rings have already been established, and several more are being prepared, according to WHO Director of Science for Health Meg Doherty. Eligible participants can receive the vaccine between one and 21 days after exposure, though scientists have not yet determined if the timing affects outcomes.

The trial is led by Congolese researchers and managed by the country's National Institute for Biomedical Research, with support from the WHO and international partners. Designed as a platform trial, TUMAINI can evaluate multiple vaccine candidates within a single research framework.

WHO advisory groups reviewed two vaccines developed specifically against the Bundibugyo virus last week: ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. Recommendations on those vaccines are expected this week.

Meg Doherty said it will likely take several months before results begin to emerge. Community members have already been approaching the trial site seeking to enroll.

Key facts

  • The first four participants in the TUMAINI clinical trial have received doses in the Democratic Republic of Congo.
  • The study evaluates if the Ervebo vaccine can reduce severe illness and death from the Bundibugyo virus.
  • The trial uses a ring-vaccination strategy to immunize people in close contact with confirmed patients.

Three perspectives

Neutral

The TUMAINI clinical trial in the Democratic Republic of Congo is evaluating the effectiveness of the Ervebo vaccine against the Bundibugyo virus.

Positive

The trial is designed as a platform that can evaluate multiple vaccine candidates within a single research framework.

Negative

Scientists have not yet determined whether the timing of the vaccine, between one and 21 days after exposure, affects outcomes.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition